Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2026 | $170.00 | Outperform | RBC Capital Mkts |
| 5/14/2026 | $155.00 | Neutral → Outperform | Daiwa Securities |
| 8/12/2025 | $94.00 | Outperform → Neutral | Daiwa Securities |
| 7/11/2025 | $125.00 | Sector Outperform → Sector Perform | Scotiabank |
| 3/4/2025 | $130.00 → $90.00 | Neutral | Citigroup |
| 2/28/2025 | $100.00 | Buy → Hold | HSBC Securities |
| 2/10/2025 | $130.00 → $100.00 | Equal Weight → Underweight | Barclays |
| 2/7/2025 | $177.00 → $140.00 | Buy → Hold | TD Cowen |
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
Integrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysis DRAGEN™ pipelines optimized for IDT custom hybrid capture panels enable accurate, efficient, variant detection The DRAGEN Somatic for IDT Custom Panels feature a new, low-quality FFPE mode to analyze challenging samples Integrated DNA Technologies (IDT), a Danaher company and global leader in genomics, today announced a strategic collaboration with Illumina, Inc. (NASDAQ:ILMN) to enable a DRAGEN™ secondary analysis pipeline for IDT xGen™ FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an
Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panelsSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to acc
An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatmentSolution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD marketSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer
RBC Capital Mkts resumed coverage of Illumina with a rating of Outperform and set a new price target of $170.00
Daiwa Securities upgraded Illumina from Neutral to Outperform and set a new price target of $155.00
Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
4 - ILLUMINA, INC. (0001110803) (Issuer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
SD - ILLUMINA, INC. (0001110803) (Filer)
8-K - ILLUMINA, INC. (0001110803) (Filer)
Veteran genomics leader joins Illumina to advance global medical strategyIllumina chief commercial officer to depart for role as a life science tools company CEO SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ:ILMN) announced the appointment of Eric D. Green, M.D., Ph.D., as Chief Medical Officer (CMO), effective February 2. In this role reporting to the CEO, Dr. Green will accelerate the company's mission to drive a revolution in medicine by unlocking the power of the genome. Dr. Green will serve as a key scientific and medical leader representing Illumina, helping advance the clinical use of genomics, expand access to precision medicine solutions, and increase the di
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as
SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results:Revenue of $1.09 billion for Q1 2026, up 4.8% from Q1 2025 (ROW1 organic revenue growth of 3.5%)GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9%GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15On April 28, 2026, our Board of Directors authorized an additional $1.5 billion in share repurchases"Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy," said Jacob Thaysen, Chief Executive Offic
SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's
Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35Fiscal year 2025 results: Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basisEx-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basisGAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84Fiscal year 2026 guidance:
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)
SC 13G - ILLUMINA, INC. (0001110803) (Subject)
SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)